Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support

BMC Bioinformatics

Proceedings

Casey Lynnette Overby¹  Ira J Kalet²  Peter Tarczy-Hornoch³  David L Veenstra⁴  James I Hoath⁵ 

[1] Department of Medical Education & Biomedical Informatics, University of Washington, Seattle, WA, USA;Department of Medical Education & Biomedical Informatics, University of Washington, Seattle, WA, USA;Department of Computer Science & Engineering, University of Washington, Seattle, WA, USA;Medical Center Information Services, University of Washington, Seattle, WA, USA;Department of Radiation Oncology, University of Washington, Seattle, WA, USA;Biological Structure, University of Washington, Seattle, WA, USA;Department of Medical Education & Biomedical Informatics, University of Washington, Seattle, WA, USA;Department of Pediatrics, University of Washington, Seattle, WA, USA;Department of Computer Science & Engineering, University of Washington, Seattle, WA, USA;Department of Pharmacy, University of Washington, Seattle, WA, USA;Medical Center Information Services, University of Washington, Seattle, WA, USA;

关键词: Clinical Decision Support;    Drug Label;    Decision Support Rule;    Computable Patient Data;    Feasible Expansion;   

DOI  :  10.1186/1471-2105-11-S9-S10

来源: Springer

【 摘 要 】

In pursuing personalized medicine, pharmacogenomic (PGx) knowledge may help guide prescribing drugs based on a person’s genotype. Here we evaluate the feasibility of incorporating PGx knowledge, combined with clinical data, to support clinical decision-making by: 1) analyzing clinically relevant knowledge contained in PGx knowledge resources; 2) evaluating the feasibility of a rule-based framework to support formal representation of clinically relevant knowledge contained in PGx knowledge resources; and, 3) evaluating the ability of an electronic medical record/electronic health record (EMR/EHR) to provide computable forms of clinical data needed for PGx clinical decision support. Findings suggest that the PharmGKB is a good source for PGx knowledge to supplement information contained in FDA approved drug labels. Furthermore, we found that with supporting knowledge (e.g. IF age <18 THEN patient is a child), sufficient clinical data exists in University of Washington’s EMR systems to support 50% of PGx knowledge contained in drug labels that could be expressed as rules.

【 授权许可】

CC BY   
© Overby et al; licensee BioMed Central Ltd. 2010